Dr. Carbone on Acquired Resistance to Osimertinib in NSCLC

Lung Cancer Update | 2022 Metro Denver Oncology Nursing Society ConferenceПодробнее

2020 TTF EGFR Breakout PIOTROWSKA Part 1 - Current Options Upon Acquired Resistance to OsimertinibПодробнее

Dr. Yang on Resistance Mechanisms from Osimertinib in NSCLCПодробнее

Acquired Resistance to Osimertinib in T790M-Positive NSCLCПодробнее

Rociletinib/Osimertinib for EGFR T790M-negative NSCLCПодробнее

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancerПодробнее

Resistance to Osimertinib in EGFR-Mutated NSCLCПодробнее

Acquired Resistance to Osimertinib in EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum - EnglishПодробнее

Dr. Goldberg on Resistance to Osimertinib for NSCLCПодробнее

Resistance to Osimertinib in EGFR-Mutated NSCLCПодробнее

Dr. Ramalingam on the Role of Osimertinib in eGFR T790M-Positive Advanced NSCLCПодробнее

EGFR Mutated NSCLC Disease Progression on Osimertinib - 2022 Program: Targeted Therapies ForumПодробнее

Dr. Wakelee on Benefits of Osimertinib in EGFR-Mutant NSCLC TreatmentПодробнее

Dr. Suresh Ramalingam on Frontline Osimertinib Data in EGFR+ NSCLCПодробнее

2020 TTF EGFR Breakout PIOTROWSKA Part 2 - Current Options Upon Acquired Resistance to OsimertinibПодробнее

Mechanisms of Resistance to Upfront EGFR-Targeted TherapyПодробнее

Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLCПодробнее

Dr. Goldberg on Options After Developing Resistance to Osimertinib for NSCLCПодробнее

Osimertinib for EGFR T790M Resistance Mutations in NSCLCПодробнее

Dr. Perez-Soler on Impact of Osimertinib on Field of NSCLCПодробнее